nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CYP2D6—Carteolol—glaucoma	0.0375	0.0922	CbGbCtD
Sorafenib—CYP1A2—Betaxolol—glaucoma	0.0308	0.0756	CbGbCtD
Sorafenib—CYP2D6—Betaxolol—glaucoma	0.0253	0.0623	CbGbCtD
Sorafenib—CYP2C19—Methazolamide—glaucoma	0.0253	0.0621	CbGbCtD
Sorafenib—CYP2C9—Diclofenamide—glaucoma	0.0244	0.0599	CbGbCtD
Sorafenib—CYP2C9—Dorzolamide—glaucoma	0.0236	0.0579	CbGbCtD
Sorafenib—CYP3A5—Clonidine—glaucoma	0.0226	0.0556	CbGbCtD
Sorafenib—CYP2C19—Timolol—glaucoma	0.0215	0.0528	CbGbCtD
Sorafenib—CYP2C9—Methazolamide—glaucoma	0.021	0.0516	CbGbCtD
Sorafenib—CYP2D6—Methazolamide—glaucoma	0.0192	0.0472	CbGbCtD
Sorafenib—CYP3A4—Pilocarpine—glaucoma	0.0181	0.0444	CbGbCtD
Sorafenib—ABCB1—Timolol—glaucoma	0.0173	0.0426	CbGbCtD
Sorafenib—CYP1A2—Clonidine—glaucoma	0.0169	0.0414	CbGbCtD
Sorafenib—CYP2D6—Timolol—glaucoma	0.0163	0.0401	CbGbCtD
Sorafenib—ABCB1—Clonidine—glaucoma	0.0147	0.0362	CbGbCtD
Sorafenib—CYP3A4—Brinzolamide—glaucoma	0.0142	0.0349	CbGbCtD
Sorafenib—CYP2D6—Clonidine—glaucoma	0.0139	0.0341	CbGbCtD
Sorafenib—CYP3A4—Dorzolamide—glaucoma	0.0137	0.0337	CbGbCtD
Sorafenib—CYP3A4—Methazolamide—glaucoma	0.0122	0.03	CbGbCtD
Sorafenib—CYP3A4—Acetazolamide—glaucoma	0.00976	0.024	CbGbCtD
Sorafenib—CYP3A4—Clonidine—glaucoma	0.00883	0.0217	CbGbCtD
Sorafenib—Vismodegib—SMO—glaucoma	0.00552	0.534	CrCbGaD
Sorafenib—Regorafenib—NTRK1—glaucoma	0.00483	0.466	CrCbGaD
Sorafenib—TIE1—endothelium—glaucoma	0.00419	0.0692	CbGeAlD
Sorafenib—FLT4—endothelium—glaucoma	0.00346	0.0572	CbGeAlD
Sorafenib—FLT1—endothelium—glaucoma	0.00269	0.0445	CbGeAlD
Sorafenib—CDK7—connective tissue—glaucoma	0.00251	0.0414	CbGeAlD
Sorafenib—KDR—endothelium—glaucoma	0.00228	0.0376	CbGeAlD
Sorafenib—ZAK—eye—glaucoma	0.00225	0.0371	CbGeAlD
Sorafenib—HIPK3—retina—glaucoma	0.00218	0.036	CbGeAlD
Sorafenib—HIPK3—connective tissue—glaucoma	0.00212	0.035	CbGeAlD
Sorafenib—KIT—endothelium—glaucoma	0.00202	0.0333	CbGeAlD
Sorafenib—EPHX2—eye—glaucoma	0.00188	0.0311	CbGeAlD
Sorafenib—EPHX2—retina—glaucoma	0.00187	0.0309	CbGeAlD
Sorafenib—FLT3—connective tissue—glaucoma	0.0018	0.0298	CbGeAlD
Sorafenib—FLT4—eye—glaucoma	0.0017	0.0281	CbGeAlD
Sorafenib—MKNK1—Pindolol—Levobunolol—glaucoma	0.0016	0.276	CbGdCrCtD
Sorafenib—MKNK1—Pindolol—Carteolol—glaucoma	0.0016	0.276	CbGdCrCtD
Sorafenib—MAP3K7—retina—glaucoma	0.00157	0.026	CbGeAlD
Sorafenib—MKNK2—eye—glaucoma	0.00154	0.0254	CbGeAlD
Sorafenib—MKNK1—Pindolol—Metipranolol—glaucoma	0.00153	0.263	CbGdCrCtD
Sorafenib—MKNK2—retina—glaucoma	0.00152	0.0252	CbGeAlD
Sorafenib—MKNK1—eye—glaucoma	0.00152	0.0251	CbGeAlD
Sorafenib—MKNK1—retina—glaucoma	0.00151	0.0249	CbGeAlD
Sorafenib—MKNK2—connective tissue—glaucoma	0.00148	0.0245	CbGeAlD
Sorafenib—RET—connective tissue—glaucoma	0.00145	0.0239	CbGeAlD
Sorafenib—RALBP1—eye—glaucoma	0.00139	0.023	CbGeAlD
Sorafenib—RALBP1—retina—glaucoma	0.00138	0.0227	CbGeAlD
Sorafenib—FLT1—eye—glaucoma	0.00132	0.0218	CbGeAlD
Sorafenib—RAF1—eye—glaucoma	0.00131	0.0217	CbGeAlD
Sorafenib—FLT1—retina—glaucoma	0.00131	0.0216	CbGeAlD
Sorafenib—FLT1—connective tissue—glaucoma	0.00127	0.021	CbGeAlD
Sorafenib—RAF1—connective tissue—glaucoma	0.00127	0.0209	CbGeAlD
Sorafenib—PDGFRA—connective tissue—glaucoma	0.00119	0.0197	CbGeAlD
Sorafenib—KDR—eye—glaucoma	0.00112	0.0185	CbGeAlD
Sorafenib—KDR—retina—glaucoma	0.00111	0.0183	CbGeAlD
Sorafenib—CSF1R—eye—glaucoma	0.00109	0.018	CbGeAlD
Sorafenib—KDR—connective tissue—glaucoma	0.00108	0.0178	CbGeAlD
Sorafenib—MKNK1—Pindolol—Betaxolol—glaucoma	0.00107	0.184	CbGdCrCtD
Sorafenib—CSF1R—connective tissue—glaucoma	0.00105	0.0174	CbGeAlD
Sorafenib—PDGFRB—eye—glaucoma	0.000967	0.016	CbGeAlD
Sorafenib—KIT—connective tissue—glaucoma	0.000954	0.0158	CbGeAlD
Sorafenib—PDGFRB—connective tissue—glaucoma	0.000932	0.0154	CbGeAlD
Sorafenib—Mental disorder—Clonidine—glaucoma	0.000303	0.00113	CcSEcCtD
Sorafenib—Shock—Pilocarpine—glaucoma	0.000303	0.00113	CcSEcCtD
Sorafenib—Thrombocytopenia—Pilocarpine—glaucoma	0.000301	0.00112	CcSEcCtD
Sorafenib—Erythema—Clonidine—glaucoma	0.000301	0.00112	CcSEcCtD
Sorafenib—Dyspepsia—Brimonidine—glaucoma	0.0003	0.00112	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000297	0.0011	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Travoprost—glaucoma	0.000296	0.0011	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000294	0.0011	CcSEcCtD
Sorafenib—Fatigue—Brimonidine—glaucoma	0.000294	0.00109	CcSEcCtD
Sorafenib—Anorexia—Pilocarpine—glaucoma	0.000293	0.00109	CcSEcCtD
Sorafenib—Hypersensitivity—Apraclonidine—glaucoma	0.000293	0.00109	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.000292	0.00109	CcSEcCtD
Sorafenib—Pain—Brimonidine—glaucoma	0.000292	0.00109	CcSEcCtD
Sorafenib—Dyspnoea—Dorzolamide—glaucoma	0.00029	0.00108	CcSEcCtD
Sorafenib—Muscle spasms—Clonidine—glaucoma	0.00029	0.00108	CcSEcCtD
Sorafenib—Dyspnoea—Travoprost—glaucoma	0.000289	0.00108	CcSEcCtD
Sorafenib—Dyspepsia—Dorzolamide—glaucoma	0.000287	0.00107	CcSEcCtD
Sorafenib—Dyspnoea—Brinzolamide—glaucoma	0.000286	0.00106	CcSEcCtD
Sorafenib—Dyspepsia—Travoprost—glaucoma	0.000286	0.00106	CcSEcCtD
Sorafenib—Asthenia—Apraclonidine—glaucoma	0.000285	0.00106	CcSEcCtD
Sorafenib—Decreased appetite—Dorzolamide—glaucoma	0.000283	0.00105	CcSEcCtD
Sorafenib—Erectile dysfunction—Timolol—glaucoma	0.000283	0.00105	CcSEcCtD
Sorafenib—Urticaria—Acetazolamide—glaucoma	0.000282	0.00105	CcSEcCtD
Sorafenib—Dyspepsia—Brinzolamide—glaucoma	0.000282	0.00105	CcSEcCtD
Sorafenib—Pruritus—Apraclonidine—glaucoma	0.000281	0.00105	CcSEcCtD
Sorafenib—Body temperature increased—Acetazolamide—glaucoma	0.000281	0.00105	CcSEcCtD
Sorafenib—Fatigue—Dorzolamide—glaucoma	0.000281	0.00105	CcSEcCtD
Sorafenib—Tinnitus—Betaxolol—glaucoma	0.000281	0.00105	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.00028	0.00104	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Travoprost—glaucoma	0.00028	0.00104	CcSEcCtD
Sorafenib—Fatigue—Travoprost—glaucoma	0.00028	0.00104	CcSEcCtD
Sorafenib—Flushing—Betaxolol—glaucoma	0.00028	0.00104	CcSEcCtD
Sorafenib—Cardiac disorder—Betaxolol—glaucoma	0.00028	0.00104	CcSEcCtD
Sorafenib—Pain—Dorzolamide—glaucoma	0.000279	0.00104	CcSEcCtD
Sorafenib—Decreased appetite—Brinzolamide—glaucoma	0.000278	0.00104	CcSEcCtD
Sorafenib—Weight decreased—Timolol—glaucoma	0.000278	0.00104	CcSEcCtD
Sorafenib—Constipation—Travoprost—glaucoma	0.000277	0.00103	CcSEcCtD
Sorafenib—Pain—Travoprost—glaucoma	0.000277	0.00103	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000276	0.00103	CcSEcCtD
Sorafenib—Asthenia—Bimatoprost—glaucoma	0.000276	0.00103	CcSEcCtD
Sorafenib—Fatigue—Brinzolamide—glaucoma	0.000276	0.00103	CcSEcCtD
Sorafenib—Angioedema—Clonidine—glaucoma	0.000275	0.00102	CcSEcCtD
Sorafenib—Dyspnoea—Pilocarpine—glaucoma	0.000274	0.00102	CcSEcCtD
Sorafenib—Pain—Brinzolamide—glaucoma	0.000274	0.00102	CcSEcCtD
Sorafenib—Angiopathy—Betaxolol—glaucoma	0.000273	0.00102	CcSEcCtD
Sorafenib—Pruritus—Bimatoprost—glaucoma	0.000273	0.00101	CcSEcCtD
Sorafenib—Immune system disorder—Betaxolol—glaucoma	0.000272	0.00101	CcSEcCtD
Sorafenib—Diarrhoea—Apraclonidine—glaucoma	0.000272	0.00101	CcSEcCtD
Sorafenib—Mediastinal disorder—Betaxolol—glaucoma	0.000271	0.00101	CcSEcCtD
Sorafenib—Dyspepsia—Pilocarpine—glaucoma	0.000271	0.00101	CcSEcCtD
Sorafenib—Syncope—Clonidine—glaucoma	0.00027	0.00101	CcSEcCtD
Sorafenib—Arrhythmia—Betaxolol—glaucoma	0.000269	0.001	CcSEcCtD
Sorafenib—Decreased appetite—Pilocarpine—glaucoma	0.000268	0.000996	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dorzolamide—glaucoma	0.000266	0.000991	CcSEcCtD
Sorafenib—Alopecia—Betaxolol—glaucoma	0.000266	0.000991	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000266	0.000989	CcSEcCtD
Sorafenib—ABCB1—retina—glaucoma	0.000266	0.00439	CbGeAlD
Sorafenib—Gastrointestinal pain—Travoprost—glaucoma	0.000265	0.000987	CcSEcCtD
Sorafenib—Loss of consciousness—Clonidine—glaucoma	0.000265	0.000985	CcSEcCtD
Sorafenib—Mental disorder—Betaxolol—glaucoma	0.000264	0.000982	CcSEcCtD
Sorafenib—Constipation—Pilocarpine—glaucoma	0.000263	0.00098	CcSEcCtD
Sorafenib—Pain—Pilocarpine—glaucoma	0.000263	0.00098	CcSEcCtD
Sorafenib—Cough—Clonidine—glaucoma	0.000263	0.000978	CcSEcCtD
Sorafenib—Dizziness—Apraclonidine—glaucoma	0.000263	0.000978	CcSEcCtD
Sorafenib—Malnutrition—Betaxolol—glaucoma	0.000262	0.000976	CcSEcCtD
Sorafenib—Erythema—Betaxolol—glaucoma	0.000262	0.000976	CcSEcCtD
Sorafenib—Urticaria—Dorzolamide—glaucoma	0.000259	0.000963	CcSEcCtD
Sorafenib—Epistaxis—Timolol—glaucoma	0.000259	0.000962	CcSEcCtD
Sorafenib—Body temperature increased—Dorzolamide—glaucoma	0.000258	0.000958	CcSEcCtD
Sorafenib—Abdominal pain—Dorzolamide—glaucoma	0.000258	0.000958	CcSEcCtD
Sorafenib—Dysgeusia—Betaxolol—glaucoma	0.000257	0.000956	CcSEcCtD
Sorafenib—Arthralgia—Clonidine—glaucoma	0.000256	0.000954	CcSEcCtD
Sorafenib—Abdominal pain—Travoprost—glaucoma	0.000256	0.000954	CcSEcCtD
Sorafenib—Asthenia—Acetazolamide—glaucoma	0.000255	0.000949	CcSEcCtD
Sorafenib—Dizziness—Bimatoprost—glaucoma	0.000255	0.000948	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000255	0.000948	CcSEcCtD
Sorafenib—Urticaria—Brinzolamide—glaucoma	0.000254	0.000947	CcSEcCtD
Sorafenib—Vomiting—Apraclonidine—glaucoma	0.000253	0.00094	CcSEcCtD
Sorafenib—Muscle spasms—Betaxolol—glaucoma	0.000252	0.000938	CcSEcCtD
Sorafenib—Gastrointestinal pain—Pilocarpine—glaucoma	0.000252	0.000937	CcSEcCtD
Sorafenib—Hypersensitivity—Brimonidine—glaucoma	0.000251	0.000935	CcSEcCtD
Sorafenib—Dry mouth—Clonidine—glaucoma	0.000251	0.000933	CcSEcCtD
Sorafenib—Dermatitis—Apraclonidine—glaucoma	0.00025	0.000931	CcSEcCtD
Sorafenib—Headache—Apraclonidine—glaucoma	0.000249	0.000926	CcSEcCtD
Sorafenib—Asthenia—Brimonidine—glaucoma	0.000245	0.000911	CcSEcCtD
Sorafenib—Infection—Clonidine—glaucoma	0.000244	0.000909	CcSEcCtD
Sorafenib—Abdominal pain—Pilocarpine—glaucoma	0.000243	0.000905	CcSEcCtD
Sorafenib—Body temperature increased—Pilocarpine—glaucoma	0.000243	0.000905	CcSEcCtD
Sorafenib—Diarrhoea—Acetazolamide—glaucoma	0.000243	0.000905	CcSEcCtD
Sorafenib—Rash—Bimatoprost—glaucoma	0.000243	0.000904	CcSEcCtD
Sorafenib—Dermatitis—Bimatoprost—glaucoma	0.000243	0.000903	CcSEcCtD
Sorafenib—Anaemia—Betaxolol—glaucoma	0.000242	0.000902	CcSEcCtD
Sorafenib—Shock—Clonidine—glaucoma	0.000242	0.0009	CcSEcCtD
Sorafenib—Connective tissue disorder—Timolol—glaucoma	0.000242	0.0009	CcSEcCtD
Sorafenib—Pruritus—Brimonidine—glaucoma	0.000241	0.000898	CcSEcCtD
Sorafenib—Headache—Bimatoprost—glaucoma	0.000241	0.000898	CcSEcCtD
Sorafenib—Nervous system disorder—Clonidine—glaucoma	0.000241	0.000897	CcSEcCtD
Sorafenib—Thrombocytopenia—Clonidine—glaucoma	0.000241	0.000896	CcSEcCtD
Sorafenib—Hypersensitivity—Dorzolamide—glaucoma	0.00024	0.000893	CcSEcCtD
Sorafenib—Hypersensitivity—Travoprost—glaucoma	0.000239	0.000889	CcSEcCtD
Sorafenib—Skin disorder—Clonidine—glaucoma	0.000239	0.000888	CcSEcCtD
Sorafenib—Nausea—Apraclonidine—glaucoma	0.000236	0.000878	CcSEcCtD
Sorafenib—Hypersensitivity—Brinzolamide—glaucoma	0.000236	0.000878	CcSEcCtD
Sorafenib—Syncope—Betaxolol—glaucoma	0.000235	0.000875	CcSEcCtD
Sorafenib—Dizziness—Acetazolamide—glaucoma	0.000235	0.000875	CcSEcCtD
Sorafenib—Anorexia—Clonidine—glaucoma	0.000234	0.000872	CcSEcCtD
Sorafenib—Asthenia—Dorzolamide—glaucoma	0.000234	0.00087	CcSEcCtD
Sorafenib—Asthenia—Travoprost—glaucoma	0.000233	0.000866	CcSEcCtD
Sorafenib—Pruritus—Dorzolamide—glaucoma	0.00023	0.000858	CcSEcCtD
Sorafenib—Loss of consciousness—Betaxolol—glaucoma	0.00023	0.000858	CcSEcCtD
Sorafenib—Asthenia—Brinzolamide—glaucoma	0.00023	0.000855	CcSEcCtD
Sorafenib—Pruritus—Travoprost—glaucoma	0.000229	0.000854	CcSEcCtD
Sorafenib—Tinnitus—Timolol—glaucoma	0.000229	0.000854	CcSEcCtD
Sorafenib—Cough—Betaxolol—glaucoma	0.000229	0.000851	CcSEcCtD
Sorafenib—Nausea—Bimatoprost—glaucoma	0.000229	0.000851	CcSEcCtD
Sorafenib—Cardiac disorder—Timolol—glaucoma	0.000228	0.00085	CcSEcCtD
Sorafenib—Hypersensitivity—Pilocarpine—glaucoma	0.000227	0.000844	CcSEcCtD
Sorafenib—Pruritus—Brinzolamide—glaucoma	0.000227	0.000843	CcSEcCtD
Sorafenib—Vomiting—Acetazolamide—glaucoma	0.000226	0.000841	CcSEcCtD
Sorafenib—Dizziness—Brimonidine—glaucoma	0.000226	0.000839	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Clonidine—glaucoma	0.000224	0.000833	CcSEcCtD
Sorafenib—Angiopathy—Timolol—glaucoma	0.000223	0.000831	CcSEcCtD
Sorafenib—Arthralgia—Betaxolol—glaucoma	0.000223	0.000831	CcSEcCtD
Sorafenib—Myalgia—Betaxolol—glaucoma	0.000223	0.000831	CcSEcCtD
Sorafenib—Diarrhoea—Dorzolamide—glaucoma	0.000223	0.000829	CcSEcCtD
Sorafenib—Headache—Acetazolamide—glaucoma	0.000223	0.000829	CcSEcCtD
Sorafenib—Immune system disorder—Timolol—glaucoma	0.000222	0.000827	CcSEcCtD
Sorafenib—Diarrhoea—Travoprost—glaucoma	0.000222	0.000826	CcSEcCtD
Sorafenib—Mediastinal disorder—Timolol—glaucoma	0.000222	0.000825	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000222	0.000825	CcSEcCtD
Sorafenib—Asthenia—Pilocarpine—glaucoma	0.000221	0.000822	CcSEcCtD
Sorafenib—Arrhythmia—Timolol—glaucoma	0.00022	0.000818	CcSEcCtD
Sorafenib—Dyspnoea—Clonidine—glaucoma	0.000219	0.000815	CcSEcCtD
Sorafenib—Diarrhoea—Brinzolamide—glaucoma	0.000219	0.000815	CcSEcCtD
Sorafenib—Dry mouth—Betaxolol—glaucoma	0.000218	0.000812	CcSEcCtD
Sorafenib—Pruritus—Pilocarpine—glaucoma	0.000218	0.00081	CcSEcCtD
Sorafenib—Alopecia—Timolol—glaucoma	0.000217	0.000809	CcSEcCtD
Sorafenib—Mental disorder—Timolol—glaucoma	0.000216	0.000802	CcSEcCtD
Sorafenib—Dizziness—Dorzolamide—glaucoma	0.000215	0.000802	CcSEcCtD
Sorafenib—Rash—Brimonidine—glaucoma	0.000215	0.0008	CcSEcCtD
Sorafenib—Dermatitis—Brimonidine—glaucoma	0.000215	0.0008	CcSEcCtD
Sorafenib—Dizziness—Travoprost—glaucoma	0.000214	0.000798	CcSEcCtD
Sorafenib—Malnutrition—Timolol—glaucoma	0.000214	0.000797	CcSEcCtD
Sorafenib—Erythema—Timolol—glaucoma	0.000214	0.000797	CcSEcCtD
Sorafenib—Headache—Brimonidine—glaucoma	0.000214	0.000795	CcSEcCtD
Sorafenib—Decreased appetite—Clonidine—glaucoma	0.000214	0.000795	CcSEcCtD
Sorafenib—Infection—Betaxolol—glaucoma	0.000213	0.000791	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Clonidine—glaucoma	0.000212	0.00079	CcSEcCtD
Sorafenib—Fatigue—Clonidine—glaucoma	0.000212	0.000789	CcSEcCtD
Sorafenib—Dizziness—Brinzolamide—glaucoma	0.000212	0.000788	CcSEcCtD
Sorafenib—Nausea—Acetazolamide—glaucoma	0.000211	0.000786	CcSEcCtD
Sorafenib—Diarrhoea—Pilocarpine—glaucoma	0.000211	0.000784	CcSEcCtD
Sorafenib—Shock—Betaxolol—glaucoma	0.000211	0.000783	CcSEcCtD
Sorafenib—Constipation—Clonidine—glaucoma	0.00021	0.000782	CcSEcCtD
Sorafenib—Pain—Clonidine—glaucoma	0.00021	0.000782	CcSEcCtD
Sorafenib—Nervous system disorder—Betaxolol—glaucoma	0.00021	0.000781	CcSEcCtD
Sorafenib—Dysgeusia—Timolol—glaucoma	0.00021	0.000781	CcSEcCtD
Sorafenib—Thrombocytopenia—Betaxolol—glaucoma	0.00021	0.00078	CcSEcCtD
Sorafenib—Skin disorder—Betaxolol—glaucoma	0.000208	0.000774	CcSEcCtD
Sorafenib—Vomiting—Dorzolamide—glaucoma	0.000207	0.000771	CcSEcCtD
Sorafenib—Rash—Dorzolamide—glaucoma	0.000205	0.000764	CcSEcCtD
Sorafenib—Dermatitis—Dorzolamide—glaucoma	0.000205	0.000764	CcSEcCtD
Sorafenib—Rash—Travoprost—glaucoma	0.000205	0.000761	CcSEcCtD
Sorafenib—Dermatitis—Travoprost—glaucoma	0.000204	0.00076	CcSEcCtD
Sorafenib—Headache—Dorzolamide—glaucoma	0.000204	0.000759	CcSEcCtD
Sorafenib—Anorexia—Betaxolol—glaucoma	0.000204	0.000759	CcSEcCtD
Sorafenib—Vomiting—Brinzolamide—glaucoma	0.000204	0.000758	CcSEcCtD
Sorafenib—Dizziness—Pilocarpine—glaucoma	0.000204	0.000757	CcSEcCtD
Sorafenib—Headache—Travoprost—glaucoma	0.000203	0.000756	CcSEcCtD
Sorafenib—Nausea—Brimonidine—glaucoma	0.000203	0.000754	CcSEcCtD
Sorafenib—Rash—Brinzolamide—glaucoma	0.000202	0.000751	CcSEcCtD
Sorafenib—Dermatitis—Brinzolamide—glaucoma	0.000202	0.000751	CcSEcCtD
Sorafenib—Gastrointestinal pain—Clonidine—glaucoma	0.000201	0.000748	CcSEcCtD
Sorafenib—Headache—Brinzolamide—glaucoma	0.000201	0.000747	CcSEcCtD
Sorafenib—Angioedema—Timolol—glaucoma	0.000196	0.000728	CcSEcCtD
Sorafenib—Vomiting—Pilocarpine—glaucoma	0.000196	0.000728	CcSEcCtD
Sorafenib—Urticaria—Clonidine—glaucoma	0.000195	0.000727	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000195	0.000726	CcSEcCtD
Sorafenib—Abdominal pain—Clonidine—glaucoma	0.000194	0.000723	CcSEcCtD
Sorafenib—Body temperature increased—Clonidine—glaucoma	0.000194	0.000723	CcSEcCtD
Sorafenib—Rash—Pilocarpine—glaucoma	0.000194	0.000722	CcSEcCtD
Sorafenib—Dermatitis—Pilocarpine—glaucoma	0.000194	0.000722	CcSEcCtD
Sorafenib—Nausea—Dorzolamide—glaucoma	0.000193	0.00072	CcSEcCtD
Sorafenib—Headache—Pilocarpine—glaucoma	0.000193	0.000718	CcSEcCtD
Sorafenib—Nausea—Travoprost—glaucoma	0.000193	0.000717	CcSEcCtD
Sorafenib—Syncope—Timolol—glaucoma	0.000192	0.000715	CcSEcCtD
Sorafenib—Dyspnoea—Betaxolol—glaucoma	0.000191	0.00071	CcSEcCtD
Sorafenib—Nausea—Brinzolamide—glaucoma	0.00019	0.000708	CcSEcCtD
Sorafenib—Dyspepsia—Betaxolol—glaucoma	0.000188	0.000701	CcSEcCtD
Sorafenib—Loss of consciousness—Timolol—glaucoma	0.000188	0.000701	CcSEcCtD
Sorafenib—Cough—Timolol—glaucoma	0.000187	0.000696	CcSEcCtD
Sorafenib—Decreased appetite—Betaxolol—glaucoma	0.000186	0.000692	CcSEcCtD
Sorafenib—Hypertension—Timolol—glaucoma	0.000185	0.000688	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000185	0.000688	CcSEcCtD
Sorafenib—Fatigue—Betaxolol—glaucoma	0.000185	0.000687	CcSEcCtD
Sorafenib—Pain—Betaxolol—glaucoma	0.000183	0.000681	CcSEcCtD
Sorafenib—Constipation—Betaxolol—glaucoma	0.000183	0.000681	CcSEcCtD
Sorafenib—Nausea—Pilocarpine—glaucoma	0.000183	0.00068	CcSEcCtD
Sorafenib—Arthralgia—Timolol—glaucoma	0.000182	0.000679	CcSEcCtD
Sorafenib—Myalgia—Timolol—glaucoma	0.000182	0.000679	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000181	0.000674	CcSEcCtD
Sorafenib—Hypersensitivity—Clonidine—glaucoma	0.000181	0.000674	CcSEcCtD
Sorafenib—Dry mouth—Timolol—glaucoma	0.000178	0.000664	CcSEcCtD
Sorafenib—Asthenia—Clonidine—glaucoma	0.000176	0.000656	CcSEcCtD
Sorafenib—Anaphylactic shock—Timolol—glaucoma	0.000175	0.000651	CcSEcCtD
Sorafenib—Pruritus—Clonidine—glaucoma	0.000174	0.000647	CcSEcCtD
Sorafenib—Infection—Timolol—glaucoma	0.000174	0.000646	CcSEcCtD
Sorafenib—Shock—Timolol—glaucoma	0.000172	0.00064	CcSEcCtD
Sorafenib—Nervous system disorder—Timolol—glaucoma	0.000171	0.000638	CcSEcCtD
Sorafenib—Urticaria—Betaxolol—glaucoma	0.00017	0.000633	CcSEcCtD
Sorafenib—Skin disorder—Timolol—glaucoma	0.00017	0.000632	CcSEcCtD
Sorafenib—Body temperature increased—Betaxolol—glaucoma	0.000169	0.00063	CcSEcCtD
Sorafenib—Diarrhoea—Clonidine—glaucoma	0.000168	0.000626	CcSEcCtD
Sorafenib—Anorexia—Timolol—glaucoma	0.000167	0.00062	CcSEcCtD
Sorafenib—Dizziness—Clonidine—glaucoma	0.000163	0.000605	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Timolol—glaucoma	0.000159	0.000593	CcSEcCtD
Sorafenib—Hypersensitivity—Betaxolol—glaucoma	0.000158	0.000587	CcSEcCtD
Sorafenib—Vomiting—Clonidine—glaucoma	0.000156	0.000582	CcSEcCtD
Sorafenib—Dyspnoea—Timolol—glaucoma	0.000156	0.00058	CcSEcCtD
Sorafenib—Rash—Clonidine—glaucoma	0.000155	0.000577	CcSEcCtD
Sorafenib—Dermatitis—Clonidine—glaucoma	0.000155	0.000576	CcSEcCtD
Sorafenib—Headache—Clonidine—glaucoma	0.000154	0.000573	CcSEcCtD
Sorafenib—Dyspepsia—Timolol—glaucoma	0.000154	0.000573	CcSEcCtD
Sorafenib—Asthenia—Betaxolol—glaucoma	0.000154	0.000571	CcSEcCtD
Sorafenib—Decreased appetite—Timolol—glaucoma	0.000152	0.000566	CcSEcCtD
Sorafenib—Pruritus—Betaxolol—glaucoma	0.000151	0.000563	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Timolol—glaucoma	0.000151	0.000562	CcSEcCtD
Sorafenib—Fatigue—Timolol—glaucoma	0.000151	0.000561	CcSEcCtD
Sorafenib—Pain—Timolol—glaucoma	0.00015	0.000556	CcSEcCtD
Sorafenib—Diarrhoea—Betaxolol—glaucoma	0.000146	0.000545	CcSEcCtD
Sorafenib—Nausea—Clonidine—glaucoma	0.000146	0.000543	CcSEcCtD
Sorafenib—Gastrointestinal pain—Timolol—glaucoma	0.000143	0.000532	CcSEcCtD
Sorafenib—Dizziness—Betaxolol—glaucoma	0.000142	0.000527	CcSEcCtD
Sorafenib—Urticaria—Timolol—glaucoma	0.000139	0.000517	CcSEcCtD
Sorafenib—Body temperature increased—Timolol—glaucoma	0.000138	0.000514	CcSEcCtD
Sorafenib—Abdominal pain—Timolol—glaucoma	0.000138	0.000514	CcSEcCtD
Sorafenib—Vomiting—Betaxolol—glaucoma	0.000136	0.000506	CcSEcCtD
Sorafenib—Rash—Betaxolol—glaucoma	0.000135	0.000502	CcSEcCtD
Sorafenib—Dermatitis—Betaxolol—glaucoma	0.000135	0.000502	CcSEcCtD
Sorafenib—Headache—Betaxolol—glaucoma	0.000134	0.000499	CcSEcCtD
Sorafenib—Hypersensitivity—Timolol—glaucoma	0.000129	0.000479	CcSEcCtD
Sorafenib—Nausea—Betaxolol—glaucoma	0.000127	0.000473	CcSEcCtD
Sorafenib—Asthenia—Timolol—glaucoma	0.000125	0.000467	CcSEcCtD
Sorafenib—Pruritus—Timolol—glaucoma	0.000124	0.00046	CcSEcCtD
Sorafenib—Diarrhoea—Timolol—glaucoma	0.00012	0.000445	CcSEcCtD
Sorafenib—Dizziness—Timolol—glaucoma	0.000116	0.00043	CcSEcCtD
Sorafenib—Vomiting—Timolol—glaucoma	0.000111	0.000414	CcSEcCtD
Sorafenib—Rash—Timolol—glaucoma	0.00011	0.00041	CcSEcCtD
Sorafenib—Dermatitis—Timolol—glaucoma	0.00011	0.00041	CcSEcCtD
Sorafenib—Headache—Timolol—glaucoma	0.00011	0.000408	CcSEcCtD
Sorafenib—Nausea—Timolol—glaucoma	0.000104	0.000386	CcSEcCtD
Sorafenib—FGFR1—Disease—NOS3—glaucoma	8.67e-06	3.5e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS3—glaucoma	8.64e-06	3.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—BAD—glaucoma	8.63e-06	3.49e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CA1—glaucoma	8.61e-06	3.48e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—CDKN1B—glaucoma	8.57e-06	3.46e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CDKN1B—glaucoma	8.57e-06	3.46e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—MTHFR—glaucoma	8.57e-06	3.46e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—MTHFR—glaucoma	8.57e-06	3.46e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EDN1—glaucoma	8.54e-06	3.45e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—APOE—glaucoma	8.54e-06	3.45e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—APOE—glaucoma	8.54e-06	3.45e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TXN—glaucoma	8.49e-06	3.43e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NOS3—glaucoma	8.46e-06	3.42e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CAV1—glaucoma	8.46e-06	3.42e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CAV1—glaucoma	8.46e-06	3.42e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	8.42e-06	3.4e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TXN—glaucoma	8.41e-06	3.4e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PTGS2—glaucoma	8.35e-06	3.37e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	8.34e-06	3.37e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTSA—glaucoma	8.34e-06	3.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN2B—glaucoma	8.31e-06	3.36e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NOS3—glaucoma	8.25e-06	3.33e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GSTM1—glaucoma	8.23e-06	3.32e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NGF—glaucoma	8.23e-06	3.32e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NGFR—glaucoma	8.2e-06	3.31e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GSTM1—glaucoma	8.15e-06	3.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CDKN1B—glaucoma	8.13e-06	3.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CDKN1B—glaucoma	8.11e-06	3.28e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—APOE—glaucoma	8.1e-06	3.27e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—APOE—glaucoma	8.08e-06	3.26e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FN1—glaucoma	8.05e-06	3.25e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FN1—glaucoma	8.05e-06	3.25e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CAV1—glaucoma	8.03e-06	3.24e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	8.02e-06	3.24e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTT1—glaucoma	8.01e-06	3.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CAV1—glaucoma	8.01e-06	3.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EDN1—glaucoma	7.98e-06	3.22e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—APOE—glaucoma	7.98e-06	3.22e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—APOE—glaucoma	7.98e-06	3.22e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—BAD—glaucoma	7.95e-06	3.21e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—BAD—glaucoma	7.95e-06	3.21e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTGS2—glaucoma	7.93e-06	3.2e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CDKN1B—glaucoma	7.91e-06	3.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTGS2—glaucoma	7.91e-06	3.19e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—CAV1—glaucoma	7.9e-06	3.19e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—CAV1—glaucoma	7.9e-06	3.19e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CA2—glaucoma	7.87e-06	3.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NGF—glaucoma	7.84e-06	3.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—C3—glaucoma	7.82e-06	3.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—glaucoma	7.8e-06	3.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NTRK1—glaucoma	7.79e-06	3.15e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS3—glaucoma	7.79e-06	3.15e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	7.68e-06	3.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FN1—glaucoma	7.64e-06	3.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FN1—glaucoma	7.62e-06	3.08e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	7.6e-06	3.07e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—BAD—glaucoma	7.55e-06	3.05e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP1B1—glaucoma	7.54e-06	3.05e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ABCA1—glaucoma	7.54e-06	3.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—BAD—glaucoma	7.53e-06	3.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CDKN1B—glaucoma	7.51e-06	3.03e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—glaucoma	7.49e-06	3.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CDKN1B—glaucoma	7.49e-06	3.03e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—C3—glaucoma	7.46e-06	3.01e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ABCA1—glaucoma	7.37e-06	2.98e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP1B1—glaucoma	7.37e-06	2.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NGF—glaucoma	7.33e-06	2.96e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CDKN1B—glaucoma	7.33e-06	2.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CDKN1B—glaucoma	7.31e-06	2.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—APOE—glaucoma	7.28e-06	2.94e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MTHFR—glaucoma	7.27e-06	2.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CAV1—glaucoma	7.21e-06	2.91e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MTHFR—glaucoma	7.21e-06	2.91e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TXN—glaucoma	7.19e-06	2.9e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN2B—glaucoma	7.18e-06	2.9e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTT1—glaucoma	7.15e-06	2.89e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CDKN1B—glaucoma	7.14e-06	2.89e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTGS2—glaucoma	7.12e-06	2.88e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NOS3—glaucoma	7.09e-06	2.87e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NOS3—glaucoma	7.03e-06	2.84e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTT1—glaucoma	6.98e-06	2.82e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—C3—glaucoma	6.97e-06	2.82e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—APOE—glaucoma	6.94e-06	2.8e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS3—glaucoma	6.94e-06	2.8e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EDN1—glaucoma	6.89e-06	2.78e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CAV1—glaucoma	6.88e-06	2.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FN1—glaucoma	6.86e-06	2.77e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—glaucoma	6.79e-06	2.74e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—BAD—glaucoma	6.78e-06	2.74e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—APOE—glaucoma	6.77e-06	2.73e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—glaucoma	6.75e-06	2.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CDKN1B—glaucoma	6.75e-06	2.73e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—APOE—glaucoma	6.71e-06	2.71e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CAV1—glaucoma	6.71e-06	2.71e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CAV1—glaucoma	6.65e-06	2.69e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—glaucoma	6.62e-06	2.67e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTT1—glaucoma	6.58e-06	2.66e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	6.56e-06	2.65e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FN1—glaucoma	6.55e-06	2.64e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTT1—glaucoma	6.52e-06	2.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CDKN1B—glaucoma	6.51e-06	2.63e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	6.5e-06	2.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—APOE—glaucoma	6.49e-06	2.62e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—BAD—glaucoma	6.47e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	6.46e-06	2.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CAV1—glaucoma	6.43e-06	2.6e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—glaucoma	6.39e-06	2.58e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—glaucoma	6.39e-06	2.58e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ABCA1—glaucoma	6.39e-06	2.58e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP1B1—glaucoma	6.39e-06	2.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—glaucoma	6.35e-06	2.56e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NGF—glaucoma	6.33e-06	2.56e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CDKN1B—glaucoma	6.14e-06	2.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FN1—glaucoma	6.12e-06	2.47e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—glaucoma	6.1e-06	2.46e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CDKN1B—glaucoma	6.09e-06	2.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—glaucoma	6.07e-06	2.45e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—glaucoma	6.05e-06	2.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—BAD—glaucoma	6.05e-06	2.44e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GSTM1—glaucoma	6.03e-06	2.44e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—C3—glaucoma	6.02e-06	2.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CDKN1B—glaucoma	6.01e-06	2.43e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—glaucoma	5.98e-06	2.41e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—glaucoma	5.98e-06	2.41e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—glaucoma	5.94e-06	2.4e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GSTM1—glaucoma	5.89e-06	2.38e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.77e-06	2.33e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCA1—glaucoma	5.7e-06	2.3e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP1B1—glaucoma	5.7e-06	2.3e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—glaucoma	5.69e-06	2.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—glaucoma	5.64e-06	2.28e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—APOE—glaucoma	5.6e-06	2.26e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTT1—glaucoma	5.57e-06	2.25e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ABCA1—glaucoma	5.56e-06	2.25e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1B1—glaucoma	5.56e-06	2.25e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CAV1—glaucoma	5.55e-06	2.24e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TXN—glaucoma	5.55e-06	2.24e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CDKN1B—glaucoma	5.54e-06	2.24e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CDKN1B—glaucoma	5.54e-06	2.24e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—glaucoma	5.47e-06	2.21e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—glaucoma	5.47e-06	2.21e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—glaucoma	5.45e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—glaucoma	5.33e-06	2.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FN1—glaucoma	5.28e-06	2.13e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.26e-06	2.12e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1B—glaucoma	5.26e-06	2.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1B—glaucoma	5.24e-06	2.12e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1B1—glaucoma	5.24e-06	2.12e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCA1—glaucoma	5.24e-06	2.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—BAD—glaucoma	5.22e-06	2.11e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—glaucoma	5.21e-06	2.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—glaucoma	5.2e-06	2.1e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCA1—glaucoma	5.2e-06	2.1e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1B1—glaucoma	5.2e-06	2.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—glaucoma	5.13e-06	2.07e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—glaucoma	5.13e-06	2.07e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—glaucoma	5.11e-06	2.06e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTM1—glaucoma	5.1e-06	2.06e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—glaucoma	5.07e-06	2.05e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—glaucoma	5.06e-06	2.04e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—glaucoma	5.03e-06	2.03e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOE—glaucoma	4.96e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CAV1—glaucoma	4.92e-06	1.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—glaucoma	4.87e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—glaucoma	4.86e-06	1.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—glaucoma	4.86e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOE—glaucoma	4.85e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CAV1—glaucoma	4.8e-06	1.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1B—glaucoma	4.72e-06	1.91e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—glaucoma	4.64e-06	1.87e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—glaucoma	4.61e-06	1.86e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—glaucoma	4.61e-06	1.86e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—glaucoma	4.61e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—glaucoma	4.6e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTM1—glaucoma	4.56e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—glaucoma	4.51e-06	1.82e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1B—glaucoma	4.51e-06	1.82e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	4.49e-06	1.82e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—glaucoma	4.49e-06	1.81e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—glaucoma	4.45e-06	1.8e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1B1—glaucoma	4.44e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCA1—glaucoma	4.44e-06	1.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—glaucoma	4.38e-06	1.77e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—glaucoma	4.37e-06	1.77e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—glaucoma	4.36e-06	1.76e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—glaucoma	4.3e-06	1.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—glaucoma	4.21e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—glaucoma	4.2e-06	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—glaucoma	4.2e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—glaucoma	4.19e-06	1.69e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—glaucoma	4.17e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAV1—glaucoma	4.16e-06	1.68e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—glaucoma	4.15e-06	1.68e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—glaucoma	4.03e-06	1.63e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—glaucoma	3.93e-06	1.59e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—glaucoma	3.93e-06	1.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—glaucoma	3.9e-06	1.58e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—glaucoma	3.86e-06	1.56e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—glaucoma	3.82e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—glaucoma	3.75e-06	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—glaucoma	3.75e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—glaucoma	3.72e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAV1—glaucoma	3.71e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—glaucoma	3.7e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—glaucoma	3.67e-06	1.48e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—glaucoma	3.66e-06	1.48e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—glaucoma	3.63e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—glaucoma	3.63e-06	1.47e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAV1—glaucoma	3.63e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—glaucoma	3.55e-06	1.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—glaucoma	3.5e-06	1.41e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—glaucoma	3.48e-06	1.41e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—glaucoma	3.48e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—glaucoma	3.45e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1B1—glaucoma	3.43e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCA1—glaucoma	3.43e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—glaucoma	3.42e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAV1—glaucoma	3.42e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—glaucoma	3.4e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAV1—glaucoma	3.39e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—glaucoma	3.37e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—glaucoma	3.32e-06	1.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—glaucoma	3.3e-06	1.33e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—glaucoma	3.3e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—glaucoma	3.15e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—glaucoma	3.14e-06	1.27e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—glaucoma	3.02e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—glaucoma	2.97e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—glaucoma	2.92e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAV1—glaucoma	2.89e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—glaucoma	2.88e-06	1.16e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—glaucoma	2.83e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—glaucoma	2.81e-06	1.13e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—glaucoma	2.74e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—glaucoma	2.74e-06	1.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—glaucoma	2.65e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—glaucoma	2.58e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—glaucoma	2.57e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—glaucoma	2.56e-06	1.03e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—glaucoma	2.51e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—glaucoma	2.42e-06	9.78e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—glaucoma	2.36e-06	9.55e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—glaucoma	2.34e-06	9.46e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—glaucoma	2.28e-06	9.23e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—glaucoma	2.25e-06	9.11e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAV1—glaucoma	2.23e-06	9.02e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—glaucoma	2.19e-06	8.84e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—glaucoma	2e-06	8.09e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—glaucoma	1.69e-06	6.82e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—glaucoma	1.54e-06	6.24e-06	CbGpPWpGaD
